

# Palladium-Catalyzed Oxidative Direct C3- and C7-Alkenylations of Indazoles: Application to the Synthesis of Gamendazole


Mohammed Naas,<sup>†,‡</sup> Saïd El Kazzouli,<sup>\*,§</sup> El Mokhtar Essassi,<sup>‡</sup> Mosto Bousmina,<sup>§</sup> and Gérald Guillaumet<sup>\*,†</sup>

<sup>†</sup>Institut de Chimie Organique et Analytique (ICOA), Université d'Orléans, UMR CNRS, 7311, BP 6759, Orléans Cedex 2 45067, France

<sup>‡</sup>Faculté des Sciences, Université Mohammed V de Rabat, BP 1014, Avenue Ibn Batouta, 10000 Rabat, Morocco

<sup>§</sup>Euromed Research Institute, Engineering Division, Euro-Mediterranean University of Fes, Fès-Shore, Route de Sidi Hrazem, 30070 Fès, Morocco

## S Supporting Information



**ABSTRACT:** The first palladium-catalyzed oxidative alkenylation of (1*H*)- and (2*H*)-indazole derivatives with various olefins is described. The use of Pd(OAc)<sub>2</sub> as the catalyst and Ag<sub>2</sub>CO<sub>3</sub> as the oxidant promoted the selective C3-monoalkenylation of (1*H*)-indazoles and (2*H*)-indazoles, affording the desired products in good yields. An original oxidative C7-alkenylation of 3-substituted (1*H*)-indazoles was also developed. The oxidative alkenylation of (1*H*)-indazole was successfully applied to the total synthesis of the drug candidate gamendazole in a step- and atom-economical fashion.


The indazole system is a ubiquitous motif found in various biologically active molecules.<sup>1</sup> Moreover, various drugs and drug candidates containing indazole have been developed such as pazopanib (Votrient),<sup>2</sup> benzydamine,<sup>3</sup> bendazac,<sup>4</sup> granisetron (Kytril),<sup>5</sup> tetrydamine (or tetridamine),<sup>6</sup> and gamendazole.<sup>7</sup> The development of new synthetic methods for the preparation of original functionalized indazoles is therefore a very attractive task. The oxidative Heck-type reaction, also called the Fujiwara–Moritani reaction, has received considerable attention during the past decade.<sup>8,9</sup> Although several heterocyclic systems have been alkenylated using this C–H/C–H alkenylation reaction,<sup>10</sup> to our knowledge, (1*H*)- and (2*H*)-indazoles including functionalized derivatives have never been used as substrates for the Fujiwara reaction. Moreover, oxidative alkenylation of the six-membered ring of 6–5-bicyclic systems containing no heteroatom on the six-membered ring and at least one heteroatom on the five-membered ring is unprecedented. Only two examples of C7-alkenylation of indole using directing groups have been reported so far.<sup>11</sup> Recently, we and others reported the direct arylation of both (1*H*)-indazole<sup>12</sup> and (2*H*)-indazole<sup>13</sup> systems. Pursuing our research program on the development of new procedures for the C–H activation of indazoles, we here report on a palladium-catalyzed oxidative C3-alkenylation of (2*H*)- and (1*H*)-indazoles

as well as C7-alkenylation of (1*H*)-indazole. We also describe a concise three-step synthesis of gamendazole using direct C3-alkenylation of (1*H*)-indazole.

We first carried out the alkenylation of 2-methyl (2*H*)-indazole **1** with ethyl acrylate in the presence of Pd(OAc)<sub>2</sub> as the catalyst and either Cu(OAc)<sub>2</sub>, CuO, or Ag<sub>2</sub>O<sub>3</sub> as the oxidant. The reactions conducted in xylene without additives afforded the C-3 alkenylated product **2** in moderate yields (44 to 70%, Table 1, entries 1–3). When AcOH, Ac<sub>2</sub>O, or AcOH/Ac<sub>2</sub>O was the additive to the reaction conditions, significant improvements in the reaction yields were noticed (Table 1, entries 4–6). Replacing the xylene solvent by dioxane in the presence or absence of additives resulted in lower yields (Table 1, entries 7–9). When Ag<sub>2</sub>CO<sub>3</sub> was used as the oxidant in the presence of AcOH/Ac<sub>2</sub>O, a very good isolated yield of compound **2** was obtained (Table 1, entry 10). Importantly, when only 5 mol % of Pd(OAc)<sub>2</sub> instead of 10 mol % was used, no significant decrease in the reaction yield was observed (Table 1, entry 11). All of the other attempts to improve the reaction yield by replacing the solvent (Table 1, entry 12), the oxidant (Table 1, entries 17 and

Received: July 24, 2015

Published: August 26, 2015

Table 1. Optimization of C3-Alkenylation of (2*H*)-Indazole 1

entry	catalyst	oxidant	additive	solvent	time (h)	yield (%)
1	Pd(OAc) <sub>2</sub> (10%)	Cu(OAc) <sub>2</sub>		xylene	24	70
2	Pd(OAc) <sub>2</sub> (10%)	CuO		xylene	18	44 (31) <sup>a</sup>
3	Pd(OAc) <sub>2</sub> (10%)	Ag <sub>2</sub> CO <sub>3</sub>		xylene	18	54 (23) <sup>a</sup>
4	Pd(OAc) <sub>2</sub> (10%)	Cu(OAc) <sub>2</sub>	AcOH	xylene	18	78
5	Pd(OAc) <sub>2</sub> (10%)	Cu(OAc) <sub>2</sub>	Ac <sub>2</sub> O	xylene	18	73
6	Pd(OAc) <sub>2</sub> (10%)	Cu(OAc) <sub>2</sub>	AcOH/Ac <sub>2</sub> O	xylene	18	79
7	Pd(OAc) <sub>2</sub> (10%)	Cu(OAc) <sub>2</sub>		dioxane	24	64
8	Pd(OAc) <sub>2</sub> (10%)	Cu(OAc) <sub>2</sub>	AcOH	dioxane	18	75
9	Pd(OAc) <sub>2</sub> (10%)	Cu(OAc) <sub>2</sub>	AcOH/Ac <sub>2</sub> O	dioxane	18	51 (24) <sup>a</sup>
10	Pd(OAc) <sub>2</sub> (10%)	Ag <sub>2</sub> CO <sub>3</sub>	AcOH/Ac <sub>2</sub> O	dioxane	18	88
11	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	AcOH/Ac <sub>2</sub> O	dioxane	18	87
12	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	AcOH/Ac <sub>2</sub> O	xylene	18	79
13	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	PivOH/Ac <sub>2</sub> O	dioxane	18	67
14	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	AcOH	dioxane	18	75
15	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	PhCOOH	dioxane	18	59
16	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	Ac <sub>2</sub> O	dioxane	18	50 (17) <sup>a</sup>
17	Pd(OAc) <sub>2</sub> (5%)	AgOAc	AcOH/Ac <sub>2</sub> O	dioxane	18	69
18	Pd(OAc) <sub>2</sub> (5%)	AgNO <sub>3</sub>	AcOH/Ac <sub>2</sub> O	dioxane	18	65
19	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	BQ/AcOH	dioxane	18	77
20	Pd(OAc) <sub>2</sub> (5%)	Ag <sub>2</sub> CO <sub>3</sub>	PhCOOH/AcOH	dioxane	18	61
21	Pd/C 5%	Ag <sub>2</sub> CO <sub>3</sub>	AcOH/Ac <sub>2</sub> O	dioxane	18	56 (24) <sup>a</sup>
22	Pd(PPh <sub>3</sub> ) <sub>4</sub> 5%	Ag <sub>2</sub> CO <sub>3</sub>	AcOH/Ac <sub>2</sub> O	dioxane	18	39 (36) <sup>a</sup>

<sup>a</sup>Amount of starting material **1** recovered.

18), the additive (Table 1, entries 19 and 20), or the catalyst (Table 1, entries 21 and 22) failed (Table 1, entries 13–23).

Under the best reaction conditions identified as follows, [5 mol % of Pd(OAc)<sub>2</sub>, 2.5 equiv of Ag<sub>2</sub>CO<sub>3</sub>, 1 equiv of AcOH/Ac<sub>2</sub>O in dioxane at 120 °C under argon], the scope and limitation of Pd-catalyzed direct alkenylation of (2*H*)-indazoles were examined. Various substituted indazoles **1** and **3a–h** were used as starting substrates in the presence of either acrylates, acrylamide, acrylonitrile, or vinylarenes as coupling partners. The treatment of indazole **1** in the presence of acrylates led to the expected products **4a–f** in very good isolated yields (77% to 93%) (Table 2). When *N*-*tert*-butylacrylamide was used as olefin, the corresponding alkenylated product **4g** was obtained in 75% yield. Moderate yields were observed when either styrene or 1-ethenyl-4-methoxybenzene was used. In these cases, the desired products **4h** and **4i** were isolated in 57% and 65% yield, respectively (Table 2). The use of acrylonitrile as coupling partner produced the alkenylated product **4j** in a moderate yield (Table 2). We then used substituted (2*H*)-indazoles as starting materials. The treatment of **3a–h** with ethyl acrylate under the optimized reaction conditions led to the expected products **4k–r** in yields ranging between 68% and 90% (Table 2).

Continuing our investigation of C–H/C–H activation of indazoles, under reaction conditions similar to those developed above, the regioselective C3-alkenylation of (1*H*)-indazole **5** was successfully achieved, producing the expected product **6** in 67% yield (Table 3, entry 1). Further modifications of the reaction parameters (e.g., oxidant and/or additive) did not lead to any significant improvement in the reaction yield (Table 3, entries 2–4).



Table 2. Scope and Limitation of the Oxidative Alkenylation of (2*H*)-Indazoles

Table 3. Optimization of C3-Alkenylation of (1H)-Indazole 5




entry	oxidant	additive	yield (%)
1	Ag <sub>2</sub> CO <sub>3</sub>	AcOH/Ac <sub>2</sub> O	67
2	Cu(OAc) <sub>2</sub>	AcOH	0 (89) <sup>a</sup>
3	Ag <sub>2</sub> CO <sub>3</sub>	PhCOOH/AcOH	27 (41) <sup>a</sup>
4	Ag <sub>2</sub> CO <sub>3</sub>	BQ/AcOH	45 (23) <sup>a</sup>

<sup>a</sup>Amount of starting material 5 recovered.

With the optimized reaction conditions in hand, we next explored the scope of the oxidative Heck-type reaction of (1H)-indazoles. In the case of nonsubstituted 1-methylindazole 5 treated by methyl acrylate, cyclohexyl acrylate, acrylonitrile, or 1-ethenyl-4-methoxybenzene, the desired C3-alkenylated products 8a–d were obtained in moderate to good yields (45 to 78%, Table 4). Indazole containing a methoxy group at the 6-position

Table 4. Results of C3-Oxidative Alkenylation of (1H)-Indazoles 5 and 7a–e



<sup>a</sup>Amount of starting material 5 recovered. <sup>b</sup>In this case, 17% of dialkenylated indazole 8l was also isolated. <sup>c</sup>In this case, the reaction times were prolonged to 48 h.


(starting material 7a) also underwent the alkenylation reaction with methyl acrylate to afford the expected product 8e in 71% yield.

As we previously reported on the direct arylation of substituted indazoles containing electron-withdrawing groups on the six-membered ring,<sup>14</sup> a competition between C3- and C7-alkenylation occurred when 1-methyl 5-nitroindazole 7b was treated by cyclohexyl acrylate, which led to two products, the C3-alkenylated product 8f and the C3-/C7-dialkenylated product 8l (Table 4). This phenomenon was not observed when 1-methyl

5-nitroindazole 7b was treated by methyl acrylate. In this case, only the C3-alkenylated product 8g was obtained. In addition, when 1-methyl-6-nitroindazole 7c was treated with cyclohexyl acrylate we isolated only the C-alkenylated product 8h. The treatment of either 1-methyl 6-nitroindazole 7c or 1-methyl 7-nitroindazole 7d by methyl acrylate led to the expected products 8i and 8j in 57 and 69% yield, respectively. Surprisingly, while the direct arylation of 4-nitroindazole 7e gave only the C7-arylated product (see our previous work),<sup>14</sup> conversely, oxidative alkenylation gave exclusively the C3-alkenylated product 8k in 54% yield.



Very interestingly, when 8f was treated with 3 equiv of cyclohexyl acrylate, the dialkenylated product 8l was obtained in 53% yield (Scheme 1). Encouraged by this result, we decided to explore the C7-alkenylation of (1H)-indazoles.

Scheme 1. C7-Alkenylation of 3-Substituted (1H)-Indazole 8f



To explore the scope and limitation of this new C7-alkenylation reaction of (1H)-indazoles, 3-phenylated indazoles 9a–h were prepared<sup>14</sup> and used as starting materials in the presence of either methyl acrylate or cyclohexyl acrylate as alkenylating agents. The reaction proceeded successfully, leading to the desired C7-alkenylated products 10a–h in moderate to good yields (Table 5). The reactions required long reaction times (48 h), however, to achieve total conversion. As expected, no reaction was observed when 3-phenylindazole containing no

Table 5. Scope and Limitation of C7-Oxidative Alkenylation of 3-Phenyl-(1H)-indazoles 9a–h




<sup>a</sup>Amount of starting material 9h recovered.

substituent on the six-membered ring **9h** was treated by acrylates; only the starting material was recovered in 74% yield.

Finally, we decided to apply our method to the synthesis of gamendazole, a drug candidate for male contraception, by using only three steps instead of the nine steps reported in the literature (Scheme 2).<sup>7</sup> The treatment of the commercially

### Scheme 2. Synthesis of Gamendazole by C3-Oxidative Alkenylation of Indazole 11



available indazole **11** by 2,4-dichloro-1-(chloromethyl)benzene led to intermediate **12** in 87% yield; we also observed the formation of a byproduct **13** in 11% yield. Regioselective C3-alkenylation of **12** with ethyl acrylate under the optimized reaction conditions gave compound **14** in 69% yield. Finally, the treatment of **14** by LiOH·H<sub>2</sub>O in a mixture of THF and MeOH led to gamendazole in 91% yield.

In conclusion, we have developed the first regioselective C3-oxidative alkenylation of both (1*H*)- and (2*H*)-indazoles. We have also applied the reaction conditions to the oxidative C7-alkenylation of 3-substituted (1*H*)-indazoles, which is also the first example of regioselective oxidative alkenylation of the six-membered rings in 6,5-heterocyclic systems without directing groups. Moreover, we highlighted the utility of our method by its application to the synthesis of the drug candidate gamendazole in only three steps.

### ■ ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b02136.

Experimental details and characterization data for all new compounds (PDF)

### ■ AUTHOR INFORMATION

#### Corresponding Authors

\*E-mail: s.elkazzouli@ueuromed.org.

\*E-mail: gerald.guillaumet@univ-orleans.fr.

#### Notes

The authors declare no competing financial interest.

### ■ REFERENCES

- (1) For a recent review on the biological activities of indazoles, see: Gaikwad, D. D.; Chapolikar, A. D.; Devkate, C. G.; Warad, K. D.; Tayade, A. P.; Pawar, R. P.; Domb, A. J. *Eur. J. Med. Chem.* **2015**, *90*, 707.
- (2) Keisner, S. V.; Shah, S. R. *Drugs* **2011**, *71*, 443.

- (3) (a) Catanese, B.; Lagana, A.; Marino, A.; Picollo, R.; Rotatori, M. *Pharmacol. Res. Commun.* **1986**, *18*, 385. (b) Baldock, G. A.; Brodie, R. R.; Chasseaud, L. F.; Taylor, T. J. *J. Chromatogr., Biomed. Appl.* **1990**, *529*, 113. (c) Lang, D. H.; Rettie, A. E. *Br. J. Clin. Pharmacol.* **2000**, *50*, 311. (d) Stormer, E.; Roots, L.; Brockmoller, J. *Br. J. Clin. Pharmacol.* **2000**, *50*, 553.

- (4) (a) Shen, H.; Gou, S.; Shen, J.; Zhu, Y.; Zhang, Y.; Chen, X. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2115. (b) Saso, L.; Silvestrini, B. *Med. Hypotheses* **2001**, *56*, 114. (c) Harding, J. J. *Drugs Aging* **1992**, *2*, 287.

- (5) (a) Chaturvedula, A.; Joshi, D. P.; Anderson, C.; Morris, R.; Sembrowich, W. L.; Banga, A. K. *Pharm. Res.* **2005**, *22*, 1313. (b) Bermudez, J.; Fake, C. S.; Joiner, G. F.; Joiner, K. A.; King, F. D.; Miner, W. D.; Sanger, G. J. *J. Med. Chem.* **1990**, *33*, 1924.

- (6) (a) Ballesteros, S.; Ramon, M. F.; Martinez-Arrieta, R. *Clin. Toxicol.* **2009**, *47*, 150. (b) Manzardo, S.; Girardello, R.; Pinzetta, A.; Coppi, G.; De Aloysio, D. *Boll. Chim. Farm.* **1992**, *131*, 113. (c) Pugliares, S.; Jacobellis, M. *Minerva Ginecol.* **1991**, *43*, 245.

- (7) (a) Veerareddy, A.; Surendrreddy, G.; Dubey, P. K. *Synth. Commun.* **2013**, *43*, 2236. (b) George, I. G.; Tash, J. S.; Chakrasali, R.; Sudhakara Rao, J.; Calvet, J. P. U.S. Patent 20090197911, 2009. (c) Tash, J. S.; Chakrasali, R.; Jakkara, S. R.; Hughes, J.; Smith, S. K.; Hornbaker, K.; Heckert, L. L.; Ozturk, S. B.; Hadden, M. K.; Kinzy, T. G.; Blagg, B. S. J.; Georg, G. I. *Biol. Reprod.* **2008**, *78*, 1139.

- (8) For recent papers on C–H alkenylation, see: Wang, D.-H.; Engle, K. M.; Shi, B.-F.; Yu, J.-Q. *Science* **2010**, *327*, 315. (b) Tsai, A. S.; Brasse, M.; Bergman, R. G.; Ellman, J. A. *Org. Lett.* **2011**, *13*, 540. (c) Liu, B.; Fan, Y.; Gao, Y.; Sun, C.; Xu, C.; Zhu, J. *J. Am. Chem. Soc.* **2013**, *135*, 468. (d) Huang, L.; Wang, Q.; Qi, J.; Wu, X.; Huang, K.; Jiang, H. *Chem. Sci.* **2013**, *4*, 2665. (e) Deb, A.; Bag, S.; Kancherla, R.; Maiti, D. *J. Am. Chem. Soc.* **2014**, *136*, 13602.

- (9) For recent review papers on C–H alkenylation, see: (a) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. *Chem. Soc. Rev.* **2011**, *40*, 5068. (b) Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. *Angew. Chem., Int. Ed.* **2012**, *51*, 10236. (c) Colby, D. A.; Tsai, A. S.; Bergman, R. G.; Ellman, J. A. *Acc. Chem. Res.* **2012**, *45*, 814. (d) Song, G.; Wang, F.; Li, X. *Chem. Soc. Rev.* **2012**, *41*, 3651. (e) Zhou, L.; Lu, W. *Chem. - Eur. J.* **2014**, *20*, 634.

- (10) For recent references on C–H alkenylation of heteroanes, see: (a) Gong, B.; Shi, J.; Wang, X.; Yan, Y.; Li, Q.; Meng, Y.; Xu, H. E.; Yi, W. *Adv. Synth. Catal.* **2014**, *356*, 137. (b) Su, Y.; Zhou, H.; Chen, J.; Xu, J.; Wu, X.; Lin, A.; Yao, H. *Org. Lett.* **2014**, *16*, 4884. (c) Kang, D.; Cho, J.; Lee, P. H. *Chem. Commun.* **2013**, *49*, 10501. (d) Liu, W.; Wang, S.; Zhang, Q.; Yu, J.; Li, J.; Xie, Z.; Cao, H. *Chem. - Asian J.* **2014**, *9*, 2436. (e) Martínez, A. M.; Rodríguez, N.; Gómez Arrayás, R.; Carretero, J. C. *Chem. Commun.* **2014**, *50*, 6105. (f) Tang, J.; Cong, M.; Xia, Y.; Quéléver, G.; Fan, Y.; Qu, F.; Peng, L. *Org. Biomol. Chem.* **2015**, *13*, 110. (g) Yan, Z.-L.; Chen, W.-L.; Gao, Y.-R.; Mao, S.; Zhang, Y.-L.; Wang, Y.-Q. *Adv. Synth. Catal.* **2014**, *356*, 1085. (h) Wu, K.; Wu, P.; Wang, L.; Chen, J.; Sun, C.; Yu, Z. *Adv. Synth. Catal.* **2014**, *356*, 3871. (i) Kim, C.-E.; Son, J.-Y.; Shin, S.; Seo, B.; Lee, P. H. *Org. Lett.* **2015**, *17*, 908.

- (11) (a) Lanke, V.; Prabhu, K. R. *Org. Lett.* **2013**, *15*, 2818. (b) Shi, J.; Yan, Y.; Li, Q.; Xu, H. E.; Yi, W. *Chem. Commun.* **2014**, *50*, 6483.

- (12) (a) Ye, M.; Edmunds, A. J. F.; Morris, J. A.; Sale, D.; Zhang, Y.; Yu, J.-Q. *Chem. Sci.* **2013**, *4*, 2374. (b) Ben-Yahia, A.; Naas, M.; El Kazzouli, S.; Essassi, E. M.; Guillaumet, G. *Eur. J. Org. Chem.* **2012**, *2012*, 7075. (c) Hattori, K.; Yamaguchi, K.; Yamaguchi, J.; Itami, K. *Tetrahedron* **2012**, *68*, 7605.

- (13) Ohnmacht, S. A.; Culshaw, A. J.; Greaney, M. F. *Org. Lett.* **2010**, *12*, 224.

- (14) Naas, M.; El Kazzouli, S.; Essassi, E. M.; Bousmina, M.; Guillaumet, G. *J. Org. Chem.* **2014**, *79*, 7286.